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Aim To determine the impact of two apparent diffusion 
coefficient (ADC) measurement techniques on diffusion-
weighted magnetic resonance images (DW MRI) on the 
assessment of rectal cancer response to neoadjuvant 
chemoradiotherapy (CRT).
Methods ADC values were measured prospectively with 
two different techniques – the first, which measures ADCs 
in the most cellular tumor parts, and the second, which 
measures the entire tumor area, in 58 patients with local-
ly advanced rectal cancer on pre-CRT and post-CRT im-
age sets. Areas under the receiver operating characteristic 
curves (AUCs) and parameters of diagnostic accuracy were 
calculated for pre- and post-CRT ADC values and numeric 
and percent ADC change for each technique to determine 
their performance in tumor response evaluation using his-
topathological tumor-regression grade as the reference 
standard.
Results The second technique yielded higher AUCs 
(0.935 vs 0.704, P < 0.001), percent-change (0.828 vs 0.636, 
P < 0.001), and numeric-change (0.866 vs 0.653, P < 0.001) 
than the first technique for post-CRT ADC. Accuracies 
for post-CRT ADC assessment were 62% for the first and 
88% for the second technique (cut-off values: 0.98 and 
1.29 × 10−3 mm2/s, respectively) and for ADC change as-
sessment, both numeric and percent, 59% and 74%, re-
spectively (cut-off values: increase of 0.18 and 0.28 × 10−3 
mm2/s; increase of 24% and 37%, respectively).
Conclusions The type of measurement technique signifi-
cantly affected ADC results. ADC measurements covering 
a larger area better predicted tumor response to therapy. 
Post-CRT ADCs, regardless of the measurement technique, 
and numeric ADC change measured in the whole tumor 
volume accurately identified non-complete responders. 
Post-CRT ADCs measured in the entire tumor area yielded 
the highest accuracy level in tumor response evaluation.
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Neoadjuvant long course combined chemoradiotherapy 
(CRT), as a first step of a standard treatment for locally ad-
vanced rectal cancer, aims to downsize and downstage 
tumor before surgery in order to increase the number of 
complete resections with no microscopic residual tumors 
(R0 resections) and thereby reduce local recurrence rate. 
In locally advanced tumors, this treatment often leads to 
excellent response. In up to 24% of patients, no residual 
tumor tissue is found in the resection specimen, corre-
sponding to complete tumor response (1). These patients 
have a better prognostic outcome than patients with re-
sidual tumor. Also, in patients with complete or significant 
response to CRT, organ saving treatment may be applied 
(1-6). To safely perform less invasive strategies, it is crucial 
to accurately select patients and reliably assess tumor re-
sponse to treatment (7,8). Tumor response is estimated by 
different imaging techniques. Since conventional magnet-
ic resonance imaging (MRI) is not sufficient for this purpose, 
functional MRI techniques, such as diffusion-weighted im-
aging (DWI) and dynamic-contrast enhanced MRI, have 
been used (9-12). DWI analyzes extracellular movement of 
water protons, which depends on tissue microarchitecture 
and can be quantitatively measured as apparent diffusion 
coefficient (ADC). It allows assessment of tumor response 
to treatment due to its superb tumor tissue definition as 
high signal intensity areas and quantitative information re-
flecting tissue cellularity. ADC has become an established 
oncologic biomarker, as lower ADC values indicate malig-
nant tissues (13-16). ADC measurements are performed by 
positioning a region of interest (ROI) in the tumor area and 
measuring ADC values within the ROI. However, it is still de-
batable whether the measurements should be performed 
within the most cellular tumor parts represented as mark-
edly restricted diffusion zones or in the larger tumor areas 
with inclusion of necrotic and fibrotic tumor parts. There-
fore, the aim of our study is to determine the impact of two 
different ADC measurement techniques on DW MR images 




Between June 2012 and January 2015 eighty patients with 
locally advanced rectal cancer (LARC) diagnosed at Centre 
for Radiology and Magnetic Resonance Imaging, Clinical 
Centre of Serbia were prospectively evaluated. The study 
was approved by institutional review board and all patients 
signed written informed consent. Inclusion criteria were 1) 
rectal adenocarcinoma detected by digital rectal exami-
nation or endoscopy and histopathologically confirmed, 
2) locally advanced disease staged at pre-CRT T2-weight-
ed MRI as T3-T4 and/or positive nodal stage (one or more 
lymph nodes larger than 5 mm and/or exhibiting hetero-
geneous signal intensity or an irregular border), 3) neoad-
juvant treatment consisting of a long course CRT (total ra-
diation dose of 50.4 Gy in 28 fractions, daily dose of 1.8 Gy, 
with concomitant chemotherapy during the first and last 
weeks of radiation therapy [5-fluorouracil at the dose of 
225 mg/m2/d, 5 days per week]), 4) surgical resection per-
formed after completion of CRT. Twenty-two patients were 
excluded because of metastatic disease (12 patients), in-
sufficient MR and/or DW image quality (5 patients), non-re-
sectable tumor (3 patients), or mucinous subtype of rectal 
cancer exhibiting predominantly high T2w signal intensity 
with very high ADC values as a consequence of the very 
low cellular density (2 patients). The final study group con-
sisted of 58 patients (38 male; mean age 61.3 years; stan-
dard deviation 11.8 years).
Reference standard
Histopathological staging served as a standard of refer-
ence and was made according to the tumor regression 
grade (TRG) (17). Grading of response was as follows: TRG 1 
(complete regression), rectal tissue specimens without vi-
able tumor cells; TRG 2, single cells or small groups of cells 
within rectal tissue specimen; TRG 3, residual cancer out-
grown by fibrosis; TRG 4, significant fibrosis outgrown by 
tumor tissue; and TRG 5, extensive residual cancer without 
fibrosis. Responder group consisted of TRG 1 and TRG 2 tu-
mors, which could be eligible for organ saving treatment, 
while non-responder group consisted of TRG 3, TRG 4, and 
TRG 5 tumors. In the non-responder group, tumors were 
further subdivided into partial responder group (TRG˝3) 
and poor responder group (TRG 4 and TRG 5).
MRI technique
Before examination, all patients underwent bowel cleans-
ing and received 20 mg of spasmolytic agent (hyoscine 
butilbromide, Buscopan, BoehringerIngelheim) intrave-
nously shortly before MRI to avoid motion artifacts due to 
bowel peristalsis. MRI examinations were performed at 1.5 
T (Magnetom, Avanto, Siemens Medical Systems, Erlan-
gen, Germany) using a phased-array body coil and spine 
array coil to optimize signal-to-noise ratio. All patents 
underwent pre-treatment MRI for primary tumor and 
nodal staging and second MRI 7-9 weeks (median 
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time 55 days, range 48-61 days) after completion of CRT 
for tumor restaging and evaluation of response to CRT. The 
median time between the first MR imaging and CRT was 
23 days (range 18-41 days). The applied imaging protocol 
consisted of the following: T2-weighted turbo spin-echo 
(TSE) sequences in three orthogonal directions, high-res-
olution T2w TSE with small field of view set perpendicular 
to the tumor axis, and an axial DWI (single-shot echo pla-
nar imaging) sequence with b values of 50, 400, and 800 s/
mm2, which was set and angulated identically to the high-
resolution T2w TSE sequence. Parallel acquisition imaging 
(GRAPPA – generalized autocalibrating partially parallel ac-
quisition) was applied to reduce the acquisition time and to 
improve image quality with acceleration factor PE = 2. ADC 
maps were generated automatically including all three dif-
fusion sensitivity values in a monoexponential decay mod-
el. The sequence parameters are shown in Table 1.
Image analysis and adC measurement techniques
All images in pre- and post-treatment sets were reviewed 
by one radiologist with six-year extensive experience in 
rectal cancer imaging, who was blinded to the patients’ 
clinical data and pathology reports. Tumor was identified 
on T2w images as a tissue exhibiting higher signal intensity 
than the muscular layer of the adjacent rectal wall, which 
corresponds to the high signal intensity area on DW imag-
es (Figure 1). ROIs were manually positioned on b 800 DW 
images and then copied and pasted to the correspond-
ing ADC maps, due to the higher resolution of DW images. 
Post-CRT measurements were performed after having re-
viewed pre-CRT MRI in order to position the ROI within the 
location of the primary tumor (Figure 2). When high signal 
intensity zones were not identified on post-CRT DWI, ROIs 
were placed in the rectal wall at the former position of tu-
mor.
ADC measurements were performed on both pre-CRT and 
post-CRT image sets by two techniques. The first tech-
nique uses three circular ROIs positioned on three differ-
ent slices containing tumor tissue within the areas of the 
most prominent restrictive diffusion (both on DW images 
and corresponding ADC maps, with exclusion of T2 shine-
trough zones), which correspond to the most cellular tu-
mor zones. Mean ADC value is calculated as average of 
taBle 1. Magnetic resonance sequence parameters. diffusion-








Repetition time, ms 3000-3600 4400
Echo time, ms   89-93   76
Echo trains per slice, n   14    1
Matrix size 208x260/169x210 296x379
Field of view, mm  210-260  380
Receiver bandwidth, Hz/pixel  120 1628
Number of excitation   2    2
Slice thickness, mm   3-5    4
Distance factor, %  10   30
Number of slices  25-40   34
Echo planar imaging factor  150   -
Acquisition time, min 2.54-3.29 1.40
FIGuRe 1. areas of rectal cancer tissue on t2-weighted im-
ages (top row) corresponded to high signal intensity areas on 
diffusion-weighted images (bottom row) in a tumor estimated 
as t3a on pre-chemoradiotherapy magnetic resonance.
FIGuRe 2. Pre-chemoradiotherapy (CRt) and post-CRt t2-
weighted (left column), diffusion-weighted images (middle 
column), and apparent diffusion coefficient (adC) (right 
column) image sets of rectal cancer estimated at pre-CRt mag-
netic resonance imaging as t3a from patient who experienced 
good response to CRt (tRG 2). numbers listed in the adC 
images indicate particular regions of interest.
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three measured ADCs. The area of every single circular ROI 
was 10-50 mm2 (mean ROI area 27, standard deviation 7.23 
mm2). The second technique uses a series of freehand ROIs 
defined on each slice containing tumor along the tumor 
borders in order to include the entire tumor area in the 
measurement (mean sum of ROI areas 3689 mm2, standard 
deviation 956 mm2) (Figure 3). Mean tumor ADC value is 
calculated as average of the measured ADC values in each 
section to obtain the representative ADC value of hetero-
geneous tumor tissue.
statistical analysis
All statistical analyses were performed using SPSS (ver-
sion 20, IBM Corp., Armonk, NY, USA) and MedCalc statis-
tical software (version 14.8.1, MedCalc Software, Ostend, 
Belgium). Paired samples t test was performed to com-
pare the mean pre- and post-CRT ADC values obtained by 
each technique. Independent samples t test was used to 
compare the mean ADC values and numeric and percent 
values of ADC change obtained by each technique in re-
sponder and non-responder group. To evaluate diagnostic 
performance of each measurement technique in assess-
ment of tumor response to therapy and to determine the 
optimal cut-off value in discriminating different levels of 
tumor response to therapy, receiver operating character-
istic (ROC) curves were generated for pre-CRT and post-
CRT measurements as well as for the numeric values and 
percentage of the ADC change. The area under the ROC 
curve (AUC) was considered as relative diagnostic accura-
cy. To compare relative diagnostic accuracy, pair-wise com-
parison of the ROC curves was performed, with 95% con-
fidence intervals (CI). Parameters of diagnostic accuracy 
(sensitivity, specificity, accuracy, positive predictive value, 
and negative predictive value) were calculated using the 
optimal cut-off value, which was determined according 
to the nearest point to the upper left corner in the ROC 
curve diagram. Differences in diagnostic performances of 
two techniques were analyzed by comparing ROC curves 
according to the method described by DeLong et al (18). 
Normally distributed data are presented as mean ± stan-
dard deviation, whereas data with not-normal distribution 
are presented as median and range. P-values lower than 
0.05 were considered significant.
Results
Patients and treatment characteristics and 
histopathological findings
All patients underwent surgical resection after completion 
of neoadjuvant treatment. The median time between the 
second MRI and surgery was 12 days (range 4-37 days). 
Low anterior resection was performed in 45 patients, ab-
dominoperineal resection in 11 patients, and extended re-
section in 2 patients. There were 9 tumors in the proximal 
rectum, 32 in the middle rectum, and 17 in the distal rec-
tum. The mean distance from anal verge was 6.5 cm (stan-
dard deviation, 2.6 cm) and the mean tumor length was 3.2 
cm (standard deviation, 1.1 cm). Histopathological analysis 
confirmed complete tumor response (ypT0/TRG 1) to CRT 
in 10 patients, grade TRG 2 in 9 patients, and partial or poor 
tumor response in 39 patients (TRG 3 22, TRG 4 15 and TRG 
5 2 specimens) (Table 2).
effects of different measurement techniques on adC 
measurements
In the whole study group, there was no significant differ-
ence between percentage of ADC change measured with 
different techniques (P = 0.065). Second technique ob-
tained significantly higher pre-CRT and post-CRT mean 
ADC values and numeric values of ADC change than first 
technique (P < 0.001) (Table 3).
Quantitative analysis of tumor response to CRt
There were no significant differences in mean (±stan-
dard deviation) pre-CRT ADC values between re-
sponder and non-responder group for both mea-
FIGuRe 3. demonstration of different apparent diffusion coef-
ficient (adC) measurement techniques obtained with circular 
(first technique) and freehand regions of interest (RoI) (second 
technique). numbers listed in the adC images indicate par-
ticular RoIs.
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surement techniques (for the first technique P = 0.381, for 
the second technique P = 0.409). There were also no signif-
icant differences between partial responder and poor re-
sponder subgroup of non-responder group for both mea-
surement techniques (for the first technique 0.78 ± 0.07 
vs 0.79 ± 0.08, for the second technique 0.86 ± 0.08 vs 
0.88 ± 0.06; P = 0.760 and P = 0.311, respectively). Post-CRT 
ADC values were significantly higher in responder than in 
non-responder group (for the first technique P = 0.006, for 
the second technique P ≤ .001). Both numeric and percent 
ADC change was significantly higher in responder group 
for both measurement techniques (for the first technique 
P = 0.025 and 0.048, respectively, for the second technique 
both P < 0.001). Also, post-CRT measurements and nu-
meric and percent ADC change were significantly higher 
in partial responder than in poor responder subgroup for 
both techniques (for the first technique P = 0.034, 0.024, 
and 0.034, respectively; for the second technique P = 0.002 
for all measurements) (Figure 4).
ROC curves were generated to evaluate diagnostic per-
formance of ADC measurement techniques in the esti-
mation of tumor response to CRT (Figure 5). Pre-CRT mea-
surements resulted in AUC of 0.572 for the first technique 
and 0.570 for the second technique, which were not sig-
nificantly different (P = 0.983). Post-CRT measurements re-
sulted in AUCs of 0.704 for the first technique and of 0.935 
for the second technique, showing significantly higher ac-
curacy of the second technique (P < 0.001). This was further 
supported by reasonably high parameters of diagnostic ac-
curacy (sensitivity 95%, specificity 85%, positive predictive 
value 75%, negative predictive value 97%, accuracy 88% 
for cut-off value of 1.29 × 10-3 mm2/s). The second tech-
nique demonstrated significantly higher diagnostic per-
formance, with AUC of 0.866 and 0.828, for numeric and 
percent ADC change, respectively, than the first technique 
(AUC = 0.653 and AUC = 0.636, respectively; both P < 0.001). 
When a post-CRT ADC value of 1.29 × 10−3 mm2/s was used 
as a cut-off value for discriminating responder group from 
non-responder group, an accuracy of 88% (51/58) was 
obtained for the second technique. The same technique 
had an accuracy of 74% (43/58) for ADC change (both nu-
meric and percent) for cut-off values of 0.28 × 10-3 mm2/s 
increase and 37% increase. The ADC measurements ob-
taBle 2. the pre-treatment magnetic resonance-estimated tumor and nodal stages and postoperative histopathological stages of 
the studied population
t0 t1 t2 t3 t4 total
Pre-treatment magnetic resonance imaging+ diffusion-weighted imaging -estimated 
tumor and nodal stages
N0 n = 0 n = 2 n = 0 n = 2
N1 n = 2 n = 15 n = 0 n = 17
N2 n = 3 n = 30 n = 6 n = 39
Total n = 5 n = 47 n = 6 n = 58
Postoperative histopathological stages
N0 n = 9 n = 3 n = 9 n = 17 n = 1 n = 39
N1 n = 1 n = 0 n = 2 n = 13 n = 1 n = 17
N2 n = 0 n = 0 n = 0 n = 2 n = 0 n = 2
Total n = 10 n = 3 n = 11 n = 32 n = 2 n = 58
taBle 3. Mean apparent diffusion coefficient (adC) values ( × 10−3 mm2/s ± standard deviation) obtained with different adC measure-
ment techniques (P values are for differences between responder and non- responder group)
technique all Responders non-responders P
First
Pre-chemoradiotherapy ADC  0.79 ± 0.07  0.80 ± 0.08  0.78 ± 0.07 0.381
Post-chemoradiotherapy ADC  1.05 ± 0.15  1.13 ± 0.11  1.02 ± 0.15 0.006
Delta ADC  0.27 ± 0.15  0.33 ± 0.13  0.24 ± 0.15 0.025
Delta ADC (%) 34.6 ± 20.3 42.2 ± 18.6 31.0 ± 20.3 0.048
second
Pre-chemoradiotherapy ADC  0.87 ± 0.07  0.88 ± 0.07  0.87 ± 0.07 0.409
Post-chemoradiotherapy ADC  1.20 ± 0.17  1.36 ± 0.08  1.12 ± 0.14 <0.001
Delta ADC  0.33 ± 0.18  0.48 ± 0.10  0.26 ± 0.16 <0.001
Delta ADC (%) 38.4 ± 21.7 54.7 ± 13.8 30.4 ± 20.4 <0.001
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tained by the first technique demonstrated lower diagnos-
tic accuracy than those obtained by the second technique 
(for the pre- and post-treatment ADC measurements 62%, 
and for the measurements of ADC change 59%) (Table 4).
FIGuRe 4. Boxplots comparing mean pre-chemoradiotherapy (CRt) apparent diffusion coefficient (adC) values, mean post-CRt 
adC values, and numeric values of adC change between pre-CRt and post-CRt measurements obtained with two different adC 
measurement techniques in the responder and non-responder group (adC values in y-axis ×10−6 mm2/s).
FIGuRe 5. Comparison of receiver operating characteristic (RoC) curves demonstrating the diagnostic performance of each appar-
ent diffusion coefficient (adC) measurement technique in the assessment of tumor response to chemoradiotherapy (CRt) based 
on pre-CRt (area under the curve [auC] 0.572 and 0.570, cut-off values 0.81 × 10−3 mm2/s and 0.91 × 10−3 mm2/s, respectively) and 
post-CRt adC measurements (auC 0.704 and 0.935, cut-off values 0.98 × 10−3 mm2/s and 1.29 × 10−3 mm2/s, respectively), numeric 
adC change values (auC 0.653 and 0.866, cut-off values +0.18 × 10−3 mm2/s and +0.28 × 10−3 mm2/s, respectively), and percent adC 
change values (auC 0.636 and 0.828, cut-off values +24% and +37%, respectively).
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dIsCussIon
To our knowledge, this is the first study comparing di-
agnostic performances of different ADC measurement 
techniques in the evaluation of tumor response to CRT. 
It demonstrated that two techniques yielded significantly 
different mean ADC values before and after CRT and nu-
meric values of ADC change in the whole study group, 
indicating that ADC measurement technique consider-
ably influences the measurement results. This finding is 
in concordance with the results of some previous stud-
ies, which showed that the variation in ROI size and po-
sitioning significantly influenced measurements (19,20). 
Our study demonstrated that the first ADC measurement 
technique, which measures the most viable solid tumor 
parts, was inferior in the assessment of rectal cancer re-
sponse to neoadjuvant CRT to the second technique. The 
second technique had significantly higher accuracy in 
predicting the level of tumor response, which was highest 
in post-treatment measurements. These findings indicate 
that ADC measurements that cover the entire tumor vol-
ume together with necrotic and fibrotic regions provide 
better results in tumor response evaluation than mea-
surements including only viable tumor areas. Similar re-
sults were obtained by Roth et al (21), who used an animal 
model to analyze pre-treatment and early post-treatment 
water diffusion parameters in response of colon carcino-
ma to different antineoplastic treatments. Also, Goh et al 
(19) demonstrated that ROI-outlined entire tumor was 
more reliable for CT perfusion measurements than the 
use of smaller ROIs.
Our study demonstrated that pre-treatment measure-
ments did not reliably discriminate between responder 
group and non-responder group of tumors, regardless of 
the measurement technique. This was further confirmed 
by the finding that pre-CRT ADCs in subgroups of partial 
responders and poor responders in the non-responder 
group did not differ significantly for both measurement 
techniques. Regarding the accuracy of pre-CRT measure-
ments, our results are concordant to the results from some 
previous studies that evaluated ADC measurements in the 
assessment of tumor response, although they did not as-
sess different measurement techniques (22-24). On the 
other hand, Sun et al (25) reported significantly lower pre-
treatment ADC values of tumors with good response to 
CRT. However, they considered tumor downstaging as a re-
sponse to therapy; tumors were divided in T-downstaged 
group, consisting of tumors that lowered T status after CRT, 
and T non-downstaged group, consisting of tumors that 
showed the same or higher T status after CRT.
With regard to post-treatment measurements and mea-
surements of ADC change, our study showed that the re-
sults of ADC measurements covering the entire tumor vol-
ume highly corresponded to the level of tumor response 
to therapy and were significantly more accurate than ADC 
measurements covering only solid tumor parts. Monguzzi 
et al (26) performed ADC measurements by placing three 
freehand ROIs outlying tumor on three slices containing 
the largest tumor area with diagnostic accuracy in tu-
mor response evaluation of AUC = 0.82-0.83 and accura-
cy = 58%-74% for post-CRT measurements and AUC = 0.64-
taBle 4. Parameters of diagnostic performance of two measurement techniques for the assessment of tumor response to chemo-
radiotherapy (CRt) based on different apparent diffusion coefficient (adC) measurements. sensitivity, specificity, positive predictive 
value, negative predictive value, and accuracy were calculated using the optimal cut-off value listed for each item
area under the receiver op-


















1st technique 0.572 (0.435-0.701)  47 (9/19) 69 (27/39) 43 (9/21)  73 (27/37) 62 (36/58) 0.81 × 10−3
2nd technique 0.570 (0.433-0.699)  42 (8/19) 82 (32/39) 53 (8/15)  74 (32/43) 69 (40/58) 0.91 × 10−3
Post-CRt adC  
1st technique 0.704 (0.570-0.817)  95 (18/19) 46 (18/39) 46 (18/39)  95 (18/19) 62 (36/58) 0.98 × 10−3
2nd technique 0.935 (0.837-0.983)  95 (18/19) 85 (33/39) 75 (18/24)  97 (33/34) 88 (51/58) 1.29 × 10−3
delta adC
1st technique 0.653 (0.517-0.773)  90 (17/19) 44 (17/39) 44 (17/39)  90 (17/19) 59 (34/58) +0.18 × 10−3
2nd technique 0.866 (0.715-0.941) 100 (19/19) 62 (24/39) 56 (19/34) 100 (24/0) 74 (43/58) +0.28 × 10−3
delta adC (%)
1st technique 0.636 (0.499-0.758)  90 (17/19) 44 (17/39) 44 (17/39)  90 (17/19) 59 (34/58) +24%
2nd technique 0.828 (0.706-0.914)  90 (17/19) 67 (26/39) 57 (17/30)  93 (26/28) 74 (43/58) +37%
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0.80 and accuracy = 81%-84% for measurements of ADC 
change, which corresponded to the results obtained by 
our second measurement technique (AUC = 0.935, accu-
racy = 88%; AUC = 0.828-0.866, accuracy = 74%, respective-
ly). Ha et al (27) reported diagnostic performance of post-
CRT ADC measurements obtained by placing at least four 
circular ROIs on each slice containing tumor (AUC = 0.705, 
accuracy = 67%), which is similar to our results for the first 
technique (AUC = 0.704, accuracy = 62%). Likewise, the re-
cent results of Cai et al (28) showed AUC = 0.64-0.66 for 
post-CRT ADC measurements obtained by three small cir-
cular 4 mm2 ROI. Sun et al (25) demonstrated significant 
difference in the mean percentage of tumor ADC change 
between T downstaged and T non-downstaged group, in-
dicating that the percentage of ADC increase during and 
after CRT may be a suitable marker of tumor downstaging. 
Our study used two measurement techniques and deter-
mined the accuracy for different levels of tumor response 
to therapy. Thus, it can be hypothesized that the larger 
measuring area yields more reliable results in terms of tu-
mor tissue characterization after neoadjuvant CRT.
Our study obtained several clinically important results. 
We observed an excellent performance of post-CRT ADC 
measurements for selection of patients eligible for surgi-
cal treatment, demonstrated by very high negative predic-
tive values (95 and 97% for the first and the second tech-
nique respectively), as well as an exquisite performance of 
numeric value of ADC change measured with the second 
technique, with negative predictive value of 100%. Also, 
we found no significant differences in diagnostic perfor-
mance between post-treatment ADC measurements and 
measurements of ADC change obtained by the second 
technique, suggesting that only post-treatment ADC mea-
surements, as a less time-consuming alternative, could 
be sufficient for tumor response evaluation, and that pre-
treatment images do not necessarily have to be evaluated. 
This is supported by an appreciable level of all parameters 
of diagnostic accuracy of post-treatment ADC measured 
with the second technique. However, in complete or near-
complete responders it could be very demanding to iden-
tify the former tumor position without comparison with 
pre-CRT images.
Our study has some limitations. Primarily, it was a single 
reader evaluation, so inter-observer variability was not an 
issue. ADC measurements are very subtle and subject to 
measuring errors, so inclusion of a second reader and eval-
uation of inter-observer variability and reproducibility of 
ADC measurements could improve the measurement ob-
jectivity. Also, the number of patients in every TRG group 
was relatively small and not sufficient to obtain an opti-
mal threshold value for predicting tumor response to ther-
apy. Thus, we formed a responder group with pathological 
complete response and almost complete response (TRG 1 
and 2), even though it is debatable whether TRG 2 patients 
are eligible for less invasive treatment possibilities.
In conclusion, the novelty of this study is that two different 
tumor ADC measurement techniques were studied for the 
first time to estimate the level of rectal cancer response 
to neoadjuvant chemoradiotherapy. It was shown that the 
type of technique applied considerably influenced ADC 
measurements results and that measurement technique 
that covered larger area of the tumor better predicted tu-
mor response to therapy. Post-treatment ADC measure-
ments regardless of the applied technique and numeric 
value of ADC change measured in whole tumor volume 
can accurately identify non-complete responders eligible 
for surgical treatment. The highest accuracy in tumor re-
sponse evaluation was obtained for post-treatment mea-
surements when analyzing the entire tumor area.
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